You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨宜明昂科一度飆升52% 授產品大中華區以外開發及商業化權利
宜明昂科-B(1541.HK)今日逆勢上升,盤初一度飆升52.78%至22港元,但隨後回落,目前升幅收窄至8%以內,報15.5港元。公司昨日收市後公佈,與Instil Bio.(TIL.US)的全資附屬公司SynBioTx Inc訂立授權及合作協議,公司將收取不超過5000萬美元的首付款及潛在近期付款,以及不超過21億美元的商業、開發及監管里程碑付款,包括不超過2.7億美元的長期開發及監管里程碑付款以及不超過18億美元的商業里程碑付款,合共不超過21.5億美元,另收取按大中華地區以外全球銷售淨額的個位數至低兩位數比例計算的特許權使用費。公司指,授予SynBioTx在大中華地區以外研究、開發及商業化若干靶向程序性細胞死亡配體1及血管內皮生長因子的雙特異性抗體包括候選產品IMM2510,以及若干靶向細胞毒性T淋巴細胞相關蛋白4的單克隆抗體包括候選產品IMM27M的獨家授權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account